Why the study?
To determine whether an efficacious drug treatment exists for cherubism based on published studies.
Does pharmacological management improve outcomes in patients with cherubism?
Does pharmacological management improve outcomes in patients with cherubism?
Current evidence is insufficient to identify an effective pharmacological treatment for cherubism due to high heterogeneity and lack of standardized reporting in case studies.
Answers are grounded in this paper and cite their sources.
No drug can be recommended for cherubism; leaves open efficacy questions pending standardized prospective studies.
Objective: The aim of this systematic review was to determine if there exists an efficacious drug treatment for cherubism, based on published studies. Methods: This systematic review included observational case studies reporting pharmacological management of cherubism. We developed specific search strategies for PubMed (including Medline), ScienceDirect, Web of Science. We evaluated the methodological quality of the included studies using criteria from the Joanna Briggs Institute's critical appraisal tools. Results: Among the 621 studies initially identified by our search script, 14 were selected for inclusion, of which five were classified as having a low risk of bias, four as having an unclear risk, and five a high risk. Overall, 18 cherubism patients were treated. The sample size in each case study ranged from one to three subjects. This review identified three types of drugs used for cherubism management: calcitonin, immunomodulators and anti-resorptive agents. However, the high heterogeneity in case reports and the lack of standardized outcomes precluded a definitive conclusion regarding the efficacy of any treatment for cherubism. Conclusions: The present systematic review could not identify an effective treatment for cherubism due to the heterogeneity and limitations of the included studies. However, in response to these shortcomings, we devised a checklist of items that we recommend authors consider in order to standardize the reporting of cherubism cases and specifically when a treatment is given toward identification of an efficacious cherubism therapy. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351044, identifier CRD42022351044.
No takes yet. Share an insight, caveat, or question.
Cailleaux et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: